Description:
<jats:sec><jats:title>Objectives</jats:title><jats:p>We assessed efficacy and safety of the Gore<jats:sup>®</jats:sup> Septal Occluder (GSO) for patent foramen ovale (PFO) closure focusing on patients with challenging septal anatomies.</jats:p></jats:sec><jats:sec><jats:title>Background</jats:title><jats:p>In times of controversial discussion whether percutaneous PFO closure is superior to medical therapy for the prevention of recurrent embolic events after cryptogenic stroke, patient selection should mainly focus on individuals with an increased likelihood that the ischaemic event is related to the PFO. In this context, specific septal anatomies—such as the presence of an atrial septal aneurysm as well as long PFO tunnel anatomy—have been associated with a higher rate of cerebrovascular accidents.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The GSO was used for PFO closure in 41 patients presenting with either atrial septal aneurysm (ASA; 27/41; 65.9%) or long PFO tunnel (> 10 mm; 32/41; 78%). Seven of these patients even presented with a tunnel length ≥ 20 mm (7/41; 17.1%). Eighteen patients had both, long‐tunnel anatomy and ASA (18/41; 43.9%).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The GSO was successfully implanted in all cases. No procedural complications occurred and all patients were discharged the day after the procedure. Short‐term follow‐up, including TEE examination, in all patients was performed 37.6 ± 9.0 days after the procedure. Mid‐term follow‐up was performed after 192.7 ± 45.3 days. Later complications occurred in 7.3% (2 new onset atrial fibrillation, 1 device thrombus). Only 3 patients (7.3%) had more than trace residual shunts at 6‐weeks follow‐up. At 6‐months follow‐up, the complete closure rate was 95.1% (39/41).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The Gore<jats:sup>®</jats:sup> Septal Occluder is an efficient device for patent foramen ovale closure in challenging anatomies, including long‐tunnel PFOs and atrial septal aneurysms.</jats:p></jats:sec>